Myelodysplastic (MDS) Syndrome and Leukemia After Autotransplantation for Lymphoma: a Multicenter Case-Control Study
Diana Stripp, MD
University of Pennsylvania Cancer
Ultima Vez Modificado: 12 de mayo del 2001
Presenter: D. J. Rizzo
Affiliation: NCI, Bethesda, MD
- Increased survival has been seen in pateints with Hodgkin?s disease and Non-Hodgkin?s lymphoma who underwent autotransplantation, with a 40-50% long-term disease-free-survival rate.
- However, previous reports indicate that pts receiving autotransplants for lymphoma have an increased risk of MDS/Leukemia.
- The separate contributions of pre-tranplant and tranplant-related therapy to this risk are not well chararcterized.
Materials and Methods:
- Case-control study of 56 pts with MDS/leukemia from 955 pts receiving autotransplants for HD and 1784 for NHL, 1989- 1995 at 12 institutes in North America with follow up through Dec. 31, 1996.
- Three age-, sex- and latency-matched controls were randomly selected for each case.
- Medical records reviewed to determine all pre- and post- transplant therapy and related procedures.
- In multivariate analyses, pre-transplant chemotherapy is the largest contributor for risk of developing MDS/leukemia. With 4- and 10- fold increased risks in pts given mechlorethamine (MOPP-like regimen) and chlorambucil (p <0.05), compared to those given only cyclophosphamide- based treatment (2 fold).
- Risk increased with increasing dose of mechlorethamine > 50 mg/m2 (Relative risk 4.8) and increasing duration of chlorambucil ( > 10mos, RR 16.8)
- For total body irradiation (TBI), no substantial increased risk observed for dose < 12Gy (RR1.4). However, for doses of 13.2 Gy, there was statistically significant 4-5 fold (p=0.02) increased risk.
- Peripheral blood vs bone marrow stem cell transplantation had statistcally significant 2 fold increased risk (p<0.05) in univariate but not in multivariate analyses.
- No assoication between graft purging or use of mobilization chemotherapy/growth factors and MDS/leukemia.
- The types and intesity of conventional pre- transplant chemotherapy has the strongest impact on developing MDS/leukemia after autotransplantation.
- Although some transplant-related factors (grafting, TBI, high dose chemotherapy, purging, priming) may also play a role these findings required confirmation on other patient populations.
- Additional information reported by presenter that 33/37 patients who had post-transplant cytogenetic study showed positivity for cytogenetic evidence for MDS. Further reviews of patients?s pre-transplant cytogenetic status of MDS is underway.
- Avoidance of using MOPP or MOPP-like regimen should be undertaken in order to decrease incidence of secondary MDS/leukemia as increasing numbers of patients undergoing bone marrow or peripheral stem cell transplantation.
OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen
Alkylating Agent Linked to Therapy-Related Leukemia
Jan 17, 2013 - For patients treated for Hodgkin's lymphoma, cumulative doses of alkylating agent is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome, according to a study published online Jan. 7 in the Journal of Clinical Oncology.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!